9 completed, 1 withdrawn. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Evusheld: new trials by email Literature Review of Evusheld trials Research Report on Evusheld
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan Evusheld - COVID-19 | Completed | AstraZeneca | 397 | 2023-12-06 | 2024-06-26 | |
| Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL EVUSHELD - Chronic Lymphocytic Leukemia, COVID-19 | Phase 2 | Withdrawn | Sunnybrook Health Sciences Centre | 2023-10-01 | 2024-04-04 | |
| eVusheld Assessment reaL wORld Effectiveness in DoD Health System EVUSHELD - COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease | Completed | AstraZeneca | 4724 | 2023-08-10 | 2024-09-19 | |
| eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services EVUSHELD - SARS-CoV-2, COVID-19 | Completed | AstraZeneca | 4000 | 2023-03-09 | 2025-01-21 | |
| eVusheld Assessment reaL wORld Effectiveness at UPMC EVUSHELD - SARS-CoV-2, COVID-19 | Completed | AstraZeneca | 4232 | 2023-01-09 | 2024-11-12 | |
| eVusheld Assessment reaL wORld Effectiveness in the VA Health System Evusheld - SARS-CoV-2, COVID-19 | Completed | AstraZeneca | 5814 | 2023-01-04 | 2024-09-03 | |
| PREP (Pre-Exposure Prophylaxis) of COVID-19 Evusheld - Immuno-Deficiency, COVID-19 | Completed | Ghady Haidar | 138 | 2022-07-26 | 2024-07-15 | |
| REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients Evusheld, Control - SARS-CoV-2 Omicron Variants | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 88 | 2022-07-08 | 2026-03-16 | |
| AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics AZD7442 - SARS-CoV-2 | Phase 1 | Completed | AstraZeneca | 46 | 2022-03-21 | 2025-04-18 |
| A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults AZD7442 IM, Placebo IM, AZD7442 IV - Coronavirus Disease 2019 (COVID-19), Healthy Volunteer | Phase 1 | Completed | AstraZeneca | 61 | 2021-10-09 | 2023-03-31 |
COVID-19 (9) · Coronavirus Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
AstraZeneca (7) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Ghady Haidar (1) · Sunnybrook Health Sciences Centre (1)
United States (5) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · United Kingdom (1)
Donald M Yealy, MD (1) · Ghady Haidar, MD (1) · Scott L DuVall, PhD (1)